Handout for

DUAL DIAGNOSIS:
An Integrated Model for the Treatment of People with Co-occurring Psychiatric and Substance Disorders in Managed Care Systems

Kenneth Minkoff, M.D.

A Videotaped Lecture Produced by:
The Mental Illness Education Project, Inc.
P.O. Box 470813
Brookline Village, MA 02447
www.miepvideos.org
DUAL DIAGNOSIS
Dr. Kenneth Minkoff

“Co-occurring Psychiatric & Substance Disorders in Managed Care Systems: Standards of Care, Practice Guidelines, Workforce Competencies & Training Curricula” - copies of this report can be obtained by visiting:

WWW.MED.UPENN.EDU/CMHPSR
click on: Publication & Presentations
click on: Managed Care

Or call: (212) 662-3886  Cost: $20.00

Individuals with Co-occurring Disorders
Principles of Successful Treatment

• Comorbidity is an expectation, NOT an exception.

• Treatment success derives from the implementation of an empathic, hopeful, continuous treatment relationship, which provides integrated treatment and coordination of care through the course of multiple treatment episodes.

• Within the context of the empathic, hopeful, continuous, integrated relationship, case management/care and empathic detachment/confrontation are appropriately balanced at each point in time.

• When substance disorder and psychiatric disorder co-exist, each disorder should be considered primary, and integrated dual primary treatment is recommended, where each disorder receives appropriately intensive diagnosis-specific treatment.

• There is no one type of dual diagnosis program or intervention. For each person, the correct treatment intervention must be individualized according to diagnosis, phase of recovery/treatment, level of functioning and/or disability associated with each disorder, and level of acuity, dangerousness, motivation, capacity for treatment adherence, and availability of continuing empathic treatment relationships and other recovery supports.
SUB-GROUPS OF PEOPLE WITH COEXISTING DISORDERS

Patients with “Dual Diagnosis” - combined psychiatric and substance abuse problems - who are eligible for services fall into four major categories.

<table>
<thead>
<tr>
<th>PSYCH. HIGH / SUBSTANCE HIGH</th>
<th>PSYCH. LOW / SUBSTANCE HIGH</th>
</tr>
</thead>
<tbody>
<tr>
<td>Serious &amp; Persistent Mental Illness with Substance Dependence</td>
<td>Psychiatrically Complicated Substance Dependence</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PSYCH. HIGH / SUBSTANCE LOW</th>
<th>PSYCH. LOW / SUBSTANCE LOW</th>
</tr>
</thead>
<tbody>
<tr>
<td>Serious &amp; Persistent Mental Illness with Substance Abuse</td>
<td>Mild Psychopathology with Substance Abuse</td>
</tr>
</tbody>
</table>

**PSYCH HIGH / SUBSTANCE HIGH**

**SERIOUS & PERSISTENT MENTAL ILLNESS WITH SUBSTANCE DEPENDENCE**

- Patients with serious and persistent mental illness, who also have alcoholism and/or drug addiction, and who need treatment for addiction, for mental illness, or for both. This may include sober individuals who may benefit from psychiatric treatment in a setting which also provides sobriety support and Twelve-step Programs.

**PSYCH LOW / SUBSTANCE HIGH**

**PSYCHIATRICALLY COMPlicated SUBSTANCE DEPENDENCE**

- Patients with alcoholism and/or drug addiction who have significant psychiatric symptomatology and/or disability but who do **NOT** have serious and persistent mental illness.
- Includes both substance-induced psychiatric disorders and substance-exacerbated psychiatric disorders.
- Includes the following psychiatric syndromes:
  - Anxiety/Panic Disorder  - Suicidality
  - Depression/Hypomania  - Violence
  - Psychosis/Confusion  - PTSD Symptoms
  - Symptoms Secondary to Misuse/Abuse of Psychotropic Medication
  - Personality Traits/Disorder

**PSYCH HIGH / SUBSTANCE LOW**

**SERIOUS & PERSISTENT MENTAL ILLNESS WITH SUBSTANCE ABUSE**

- Patients with serious and persistent mental illness (e.g. Schizophrenia, Major Affective Disorders with Psychosis, Serious PTSD) which is complicated by substance abuse, whether or not the patient sees substances as a problem.

**PSYCH LOW / SUBSTANCE LOW**

**MILD PSYCHOPATHOLOGY WITH SUBSTANCE ABUSE**

- Patients who usually present in outpatient setting with various combinations of psychiatric symptoms (e.g. anxiety, depression, family conflict) and patterns of substance misuse and abuse, but not clear cut substance dependence.
DSM III-R Diagnostic Criteria

PSYCHOACTIVE SUBSTANCE ABUSE

• A maladaptive pattern of psychoactive substance use leading to clinically significant impairment or distress, as manifested by one (or more) of the following, occurring within a 12-month period:
  • Recurrent substance use resulting in failure to fulfill major role obligations at work, school, or home
  • Recurrent substance use in situations in which it is physically hazardous
  • Recurrent substance-related legal problems
  • Continued substance use despite having persistent or recurrent social or interpersonal problems caused or exacerbated by the effects of the substance use
• The symptoms have never met the criteria for Substance Dependence for this class of substance.

DSM IV Diagnostic Criteria

PSYCHOACTIVE SUBSTANCE DEPENDENCE

• A maladaptive pattern of substance use, leading to clinically significant impairment or distress, as manifested by three (or more) of the following, occurring any time in the same 12-month period:
  – Tolerance, as defined by either of the following:
    • A need for markedly increased amounts of substance to achieve intoxication or desired effect
    • Markedly diminished effect with continued use of the same amount of the substance
  – Withdrawal, as manifested by either of the following:
    • The characteristic withdrawal syndrome for the substance
    • The same (or closely related) substance is taken to relieve or avoid withdrawal symptoms
• The substance is often taken in larger amounts or over a longer period than was intended
• There is a persistent desire or unsuccessful efforts to cut down or control substance use
• A great deal of time spent in activities necessary to obtain the substance, use the substance, or recover from its effects
• Important social, occupation, or recreational activities are given up or reduced because of substance use
• Continued use despite knowledge of having a persistent or recurrent physical or psychological problem that is likely to have been caused or exacerbated by the substance

NOTE: The following items may not apply to cannabis, hallucinogens, or phencyclidine (PCP)
• Characteristic withdrawal symptoms
• Substance often taken to relieve or avoid withdrawal symptoms
Philosophical & Clinical

**BARRIERS TO INTEGRATED TREATMENT**

<table>
<thead>
<tr>
<th><strong>Addiction System</strong></th>
<th><strong>Mental Health System</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Peer Counseling model vs.</td>
<td>Medical/Professional model</td>
</tr>
<tr>
<td>Spiritual Recovery vs.</td>
<td>Scientific treatment</td>
</tr>
<tr>
<td>Self Help vs.</td>
<td>Medication</td>
</tr>
<tr>
<td>Confrontation and expectation vs.</td>
<td>Individualized support and flexibility</td>
</tr>
<tr>
<td>Detachment/empowerment vs.</td>
<td>Case management/care</td>
</tr>
<tr>
<td>Episodic treatment vs.</td>
<td>Continuity of Responsibility</td>
</tr>
<tr>
<td>Recovery ideology vs.</td>
<td>Deinstitutionalization ideology</td>
</tr>
<tr>
<td>Psychopathology is secondary to addiction</td>
<td>Substance use is secondary to psychopathology</td>
</tr>
</tbody>
</table>

**PARALLELS**

<table>
<thead>
<tr>
<th><strong>Alcoholism/Addiction</strong></th>
<th><strong>Major Mental Illness</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>1. A biological illness</td>
<td>1. A biological illness</td>
</tr>
<tr>
<td>3. Chronicity</td>
<td>3. Chronicity</td>
</tr>
<tr>
<td>4. Incurability</td>
<td>4. Incurability</td>
</tr>
<tr>
<td>5. Leads to lack of control of behavior and emotions</td>
<td>5. Leads to lack of control of behavior and emotions</td>
</tr>
<tr>
<td>6. Positive and negative symptoms</td>
<td>6. Positive and negative symptoms</td>
</tr>
<tr>
<td>7. Affects the whole family</td>
<td>7. Affects the whole family</td>
</tr>
<tr>
<td>8. Progression of the disease without treatment</td>
<td>8. Progression of the disease without treatment</td>
</tr>
<tr>
<td>9. Symptoms can be controlled with proper treatment</td>
<td>9. Symptoms can be controlled with proper treatment</td>
</tr>
<tr>
<td>10. Disease of denial, relates to both disease &amp; chronicity of disease</td>
<td>10. Disease of denial, relates to both disease &amp; chronicity of disease</td>
</tr>
<tr>
<td>11. Facing the disease can lead to depression and despair</td>
<td>11. Facing the disease can lead to depression and despair</td>
</tr>
<tr>
<td>12. Disease is often seen as a “moral issue”, due to personal weakness rather than biological causes</td>
<td>12. Disease is often seen as a “moral issue”, due to personal weakness rather than biological causes</td>
</tr>
<tr>
<td>15. Physical, mental and spiritual disease</td>
<td>Physical, mental and spiritual disease</td>
</tr>
</tbody>
</table>
PARALLELS
PROCESS OF RECOVERY

• PHASE 1: Stabilization
  - Stabilization of active substance use or acute psychiatric symptoms

• PHASE 2: Engagement/Motivational Enhancement
  - Engagement in treatment
  - Contemplation, Preparation, Persuasion

• PHASE 3: Prolonged Stabilization
  - Active treatment, Maintenance, Relapse Prevention

• PHASE 4: Recovery & Rehabilitation
  - Continued sobriety and stability
  - One year - ongoing

PROCESS OF RECOVERY
PHASE 1: Stabilization

**Detoxification**
- Usually inpatient, may be involuntary
- Usually need medication
- 3-5 days (alcohol)
- Includes assessment for other diagnoses

**Stabilize Acute Psychiatric Illness**
- Usually inpatient, may be involuntary
- Medication
- 2 weeks to 6 months
- Includes assessment for effects of substance, and for addiction

PROCESS OF RECOVERY
PHASE 2: Engagement/Motivational Enhancement

**Addiction Treatment**
- Engagement in ongoing treatment is crucial for recovery to proceed
- Begins with empathy and proceeds through phases of education and empathic confrontation, before patient commits to ongoing active treatment
- Motivational interviewing techniques
- Education about substance use, abuse, and dependence & empathic confrontation of adverse consequences are tools to overcome denial. Patient accepts powerlessness to control drug without help
- Education of the family, & involving them in interviews to promote motivation
- Engagement may take place in a variety of treatment settings...may need extended inpatient or day treatment rehabilitation (2-12 weeks)
- Engagement may be initially coerced
- Multiple cycles of relapse usually occur before engagement in ongoing treatment is successful (revolving door)

**Psychiatric Treatment**
- Engagement in ongoing treatment is crucial for recovery to proceed
- Begins with empathy and proceeds through phases of education and empathic confrontation, before patient commits to ongoing active treatment
- Motivational interviewing techniques
- Education about mental illness and the adverse consequences of treatment non-compliance are tools to overcome denial. Patient accepts powerlessness to control symptoms without help
- Education of the family, & involving them in setting limits on non-compliance
- Engagement may take place in a variety of treatment settings...may need extended inpatient or day treatment rehabilitation (1-6 months)
- Engagement may be initially coerced
- Multiple cycles of relapse usually occur before engagement in ongoing treatment is successful (revolving door)
## PROCESS OF RECOVERY
### PHASE 3: Prolonged Stabilization

<table>
<thead>
<tr>
<th>Continued Abstinence</th>
<th>Continued Medication Compliance</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>One-Year</strong></td>
<td><strong>One-Year</strong></td>
</tr>
<tr>
<td>Patient consistently attends abstinence support programs</td>
<td>Patient consistently takes medication and attends treatment sessions regularly</td>
</tr>
<tr>
<td>Usually voluntary, but ongoing compliance may be coerced or mandated</td>
<td>Usually voluntary, but may be coerced or mandated</td>
</tr>
<tr>
<td>Ongoing education about addiction, recovery and skills to maintain abstinence</td>
<td>Ongoing education about mental illness, recovery and skills to prevent relapse</td>
</tr>
<tr>
<td>Focus on asking for help to cope with urges to use substances and drop out of treatment</td>
<td>Focus on asking for help to cope with continuing symptoms and urges to discontinue treatment</td>
</tr>
<tr>
<td>Must learn to accept the illness and deal with shame, stigma, guilt, and despair</td>
<td>Must learn to accept the illness and deal with shame, stigma, guilt, and despair</td>
</tr>
<tr>
<td>Must learn to cope with “negative symptoms”: social, affective, cognitive, and personality development</td>
<td>Must learn to cope with “negative symptoms”: impaired cognition, affect, social skills, and lack of motivation/energy</td>
</tr>
<tr>
<td>Family needs ongoing involvement in its own program of recovery to learn empathic detachment and how to set caring limits</td>
<td>Family needs ongoing involvement in its own program of recovery to learn empathic detachment and how to set caring limits</td>
</tr>
<tr>
<td>May need intensive outpatient treatment and/or 6-12 months residential placement</td>
<td>May need extended hospital, day treatment and/or residential placement</td>
</tr>
<tr>
<td>Continuing assessment</td>
<td>Continuing assessment</td>
</tr>
<tr>
<td>Risk of relapse continues</td>
<td>Risk of relapse continues</td>
</tr>
</tbody>
</table>

### PHASE 4: Recovery & Rehabilitation

<table>
<thead>
<tr>
<th>Continued Sobriety</th>
<th>Continued Stability</th>
</tr>
</thead>
<tbody>
<tr>
<td>Voluntary, active involvement in treatment</td>
<td>Voluntary, active involvement in treatment</td>
</tr>
<tr>
<td>Stability precedes growth; no growth is possible unless sobriety is fairly secure. Growth occurs slowly (One Day at a Time)</td>
<td>Stability precedes growth; no growth is possible unless stabilization of illness is fairly solid. Growth occurs slowly (One Day at a Time)</td>
</tr>
<tr>
<td>Continued work in the AA program, on growing, changing, dealing with feelings</td>
<td>Continued medication, but reduction to lowest level needed for maintenance. Continued work in treatment program</td>
</tr>
<tr>
<td>Thinking begins to clear</td>
<td>Thinking begins to clear</td>
</tr>
<tr>
<td>New skills for dealing with feelings, situations</td>
<td>New skills dealing with feelings, situations</td>
</tr>
<tr>
<td>Increasing responsibility for illness, and recovery program brings increasing control of one’s life</td>
<td>Increasing responsibility for illness, and recovery programs brings increasing control of one’s life</td>
</tr>
<tr>
<td>Increasing capacity to work and to have relationships</td>
<td>Increasing capacity to work and relate (voc rehab, clubhouse)</td>
</tr>
<tr>
<td>Recovery is never “complete”, always ongoing</td>
<td>Recovery is never “complete”, always ongoing</td>
</tr>
<tr>
<td>Eventual goal is peace of mind and serenity (Serenity Prayer)</td>
<td>Eventual goal is peace of mind and serenity (Serenity Prayer)</td>
</tr>
</tbody>
</table>
Individuals with Co-occurring Disorders

Treatment Rules

• All good treatment proceeds from empathic, hopeful, clinical relationship.
• Consequently, promote opportunities to initiate and maintain continuing empathic, hopeful relationships whenever possible.
• Specifically, remove arbitrary barriers to initial assessment and evaluation, including initial psychopharmacology evaluation (e.g., length of sobriety, alcohol level, etc.)
• Moreover, never discontinue medication for a known serious mental illness because a patient is using substances.
• Never deny access to substance disorder evaluation and/or treatment because a patient is on a prescribed non-addictive psychotropic medication.
• In fact, when mental illness and substance disorder co-exist, both disorders require specific and appropriately intensive primary treatment.
• There are no rules! The specific content of dual primary treatment for each person must be individualized according to diagnosis, phase of treatment, level of functioning and/or disability, and assessment of level of care based on acuity, severity, medical safety, motivation, and availability of recovery support.

This handout may be duplicated. Additional copies may be downloaded by visiting our website: www.miepvideos.org
or by sending your request and $3.00 to:
The Mental Illness Education Project, P.O. Box 470813, Brookline Village, MA 02447
Attn: Discussion Notes.

For more information about Dr. Kenneth Minkoff, please visit his website at:
www.kenminkoff.com
The Mental Illness Education Project seeks to improve understanding of mental illness through the production of video-based programs for use by people with psychiatric conditions, their families, mental health practitioners, administrators, and educators, as well as the general public.

Our videotapes and books are particularly concerned with providing an insight into the nature of mental illness and providing a glimpse of the psychiatric challenges that many people live with. We offer visions of recovery and hope. We strive to address the pervasive issues of prejudice and discrimination through first-hand accounts of personal experience.

We are a nonprofit 501(c)(3) corporation and welcome your tax-deductible contributions.

**Principal Advisors:**

Nancy C. Andreasen, M.D., Ph.D.  
Moe Armstrong, M.A.  
Frederick J. Frese, Ph.D.  
Dale Johnson, Ph.D.  
Dennis McCrory, M.D.  
Kenneth Terkelsen, M.D.  
William A. Anthony, Ph.D.  
Kayla F. Bernheim, Ph.D.  
Agnes B. Hatfield, Ph.D.  
Harriet Lefley, Ph.D.  
LeRoy Spaniol, Ph.D.  
Lyman Wynne, M.D., Ph.D.

**Executive Director:** Christine Ledoux  
**Project Director:** Jack Churchill

Send requests for our latest catalog, comments, inquiries, and your tax-deductible contributions to:

The Mental Illness Education project, Inc.  
P.O. Box 470813  
Brookline Village, MA 02447 USA

To purchase additional videotapes, call or write:

The Mental Illness Education Project Videos  
22-D Hollywood Ave.  
Ho-Ho-kus, NJ 07423 1- 800-343-5540.

Or visit our website at:

www.miepvideos.org